<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02869074</url>
  </required_header>
  <id_info>
    <org_study_id>PCM-EVW-ES.SPANISH REGISTRY</org_study_id>
    <nct_id>NCT02869074</nct_id>
  </id_info>
  <brief_title>Molecular and Clinical Profile of Von Willebrand Disease in Spain</brief_title>
  <acronym>PCM-EVW-ES</acronym>
  <official_title>Molecular and Clinical Profile of Von Willebrand Disease (VWD) in Spain (PCM-EVW-ES). Recruitment Extension, Further Data Analysis, Improvement of Registry Platform, Diagnosis and Management of VWD Application Development</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Society of Thrombosis and Haemostasis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Francisco Vidal Pérez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maria Fernanda López Fernández</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Almudena Pérez Rodríguez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Irene Corrales Insa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ana Rosa Cid Haro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Society of Thrombosis and Haemostasis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present Project is a third phase of the previous PCM-EVW-ES Project (Batlle et al. Thromb
      &amp; Haemost 2015) with the aim of its extension, further analysis with an innovation
      development in the field of von Willebrand disease (VWD) based in the newer recently
      available methodologies. The aim of this project is to help the physician in a more uniform
      characterization and therapy of VWD in clinical practice, at an international level. A
      reduction of the expenses in the diagnosis process by using the new methodologies is pursued.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present Project is a third phase of the previous PCM-EVW-ES Project (Batlle et al. Thromb
      &amp; Haemost 2015) with the aim of its extension, further analysis with an innovation
      development in the field of von Willebrand disease (VWD) based in the newer recently
      available methodologies. The aim of this project is to help the physician in a more uniform
      characterization and therapy of VWD in clinical practice, at an international level. A
      reduction of the expenses in the diagnosis process by using the new methodologies is pursued.

      The specific objectives and corresponding tasks of the present project are as follows:

      1. Extension of the central phenotypic and next generation sequencing (NGS) genotypic
      characterization of the VWD in Spain, through the prospective recruitment in the Spanish VWD
      cohort of approximately 500 new patients with local historical VWD diagnosis (from
      approximately 38 centres).

      i. Improvement of the registry portal and database. ii. Recruitment criteria, phenotypic and
      genetic analysis of new recruited patients. In silico studies of novel von Willebrand factor
      gene (VWF) mutations iii. Analysis/investigation of the potential interrelationship between
      different clinical, phenotypic and genetic variations of the all recruited patients. iv.
      Validation/confirmation of the PCM-EVW-ES of the new initial diagnostic proposed algorithm
      including VWF NGS analysis. This project involves leading innovation and translational
      research with a direct impact on the quality of clinical care (applicability). To our
      knowledge there is no similar project in this field. Potential patents may derive from this
      project. It involves also development of e-learning and new information technologies (debates
      forum, ads, google search engine). This project may promote international collaboration.

      Development of an algorithmic platform that facilitates diagnosis and therapy orientation of
      VWD in clinical practice using the selected data from the overwhelming amount of information
      that new technologies, such as NGS, are producing.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 3, 2017</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Central diagnosis of 400 new VWD Spanish patients</measure>
    <time_frame>January 2019</time_frame>
    <description>Phenotype and genetic central diagnosis of 400 new VWD Spanish patients. With determinations in samples obtained after patients recruitment, VWF NGS sequencing carried out in all patients, for exons 1 to 52, adjacent intronic regions and aproximately 1300 bp of promotor region.
A pheno-genotype will be made With a final diagnosis assignment Evaluation of pheno/genotype congruence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PCM-EVW-ES project algorithm validation/confirmation</measure>
    <time_frame>January 2019</time_frame>
    <description>Evaluation of the algorithm with data from the Spanish Registry patients. Mutation results will be used in the first line of VWD diagnosis Correlation between mutations and phenotype</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential collaboration with the International Society on Thrombosis and Haemostasis</measure>
    <time_frame>January 2019</time_frame>
    <description>Proposal for evaluation of the PCM-EVW-ES algorithm with data from other international VWD patients cohorts</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Von Willebrand Disease</condition>
  <arm_group>
    <arm_group_label>VWD Spanish Cohort</arm_group_label>
    <description>Patients with previously diadnosis of VWD from approximately 38-40 different centers from Spain.
Samples from these patients will be analyzed locally, and also centrally for VWF and VWFgene</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>VWF gene analysis</intervention_name>
    <description>52 exons adjacent intronic regions and promotor of VWF will be analyzed</description>
    <arm_group_label>VWD Spanish Cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      EDTA-Blood 5 mL Citrated Blood 5 mL
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Up to 400 new patients (not previously recruited for the Spanish Registry) locally
        diagnosed of VWD.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: One or more of the following:

          1. VWF ≤ 30 IU/d, in 2 or more occasions.

          2. Presence of multimeric abnormalities.

          3. If isolated FVIII deficiency demonstration of decreased FVIII binding.

          4. Presence of some VWF mutation.

          5. ↑ RIPA at low concentrations of ristocetin.

        Exclusion Criteria:

          1. Presence of any data suggesting AVWS.

          2. Absence of a signed patient informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Javier BATLLE, PhD, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Complexo Hospitalario Universitario A Coruña. INIBIC. A Coruña. Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francisco Javier BATLLE, PhD, MD</last_name>
    <phone>+34 981 232174</phone>
    <email>Francisco.Javier.Batlle.Fonrodona@sergas.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Fernanda LOPEZ, PhD, MD</last_name>
    <phone>+34 981 176645</phone>
    <email>Maria.Fernanda.Lopez.Fernandez@sergas.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inmaculada Soto Ortega, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Francisco Javier B Fonrodona</last_name>
      <phone>630857525</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Lillicrap D. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Hematology Am Soc Hematol Educ Program. 2013;2013:254-60. doi: 10.1182/asheducation-2013.1.254. Review.</citation>
    <PMID>24319188</PMID>
  </reference>
  <results_reference>
    <citation>Batlle J, Pérez-Rodríguez A, Corrales I, López-Fernández MF, Rodríguez-Trillo Á, Lourés E, Cid AR, Bonanad S, Cabrera N, Moret A, Parra R, Mingot-Castellano ME, Balda I, Altisent C, Pérez-Montes R, Fisac RM, Iruín G, Herrero S, Soto I, de Rueda B, Jiménez-Yuste V, Alonso N, Vilariño D, Arija O, Campos R, Paloma MJ, Bermejo N, Toll T, Mateo J, Arribalzaga K, Marco P, Palomo Á, Sarmiento L, Iñigo B, Nieto Mdel M, Vidal R, Martínez MP, Aguinaco R, César JM, Ferreiro M, García-Frade J, Rodríguez-Huerta AM, Cuesta J, Rodríguez-González R, García-Candel F, Cornudella R, Aguilar C, Borràs N, Vidal F. Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm. Thromb Haemost. 2016 Jan;115(1):40-50. doi: 10.1160/TH15-04-0282. Epub 2015 Aug 6.</citation>
    <PMID>26245874</PMID>
  </results_reference>
  <results_reference>
    <citation>Batlle J, Perez-Rodriguez A, Pinto JC, Fraga EL, Rodriguez-Trillo Tch A, Fernanda Lopez-Fernandez M. Diagnosis and management of von Willebrand disease in Spain. Semin Thromb Hemost. 2011 Jul;37(5):503-10. doi: 10.1055/s-0031-1281036. Epub 2011 Nov 18.</citation>
    <PMID>22102193</PMID>
  </results_reference>
  <results_reference>
    <citation>Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Hashemi Soteh M, Baronciani L, Hallden C, Guilliatt A, Lester W, Peake I. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood. 2007 Jan 1;109(1):112-21. Epub 2006 Sep 19. Erratum in: Blood. 2008 Mar 15;111(6):3299-300.</citation>
    <PMID>16985174</PMID>
  </results_reference>
  <results_reference>
    <citation>Hashemi Soteh M, Peake IR, Marsden L, Anson J, Batlle J, Meyer D, Fressinaud E, Mazurier C, Goudemand J, Eikenboom J, Goodeve A; MCMDM-1VWD Study Group. Mutational analysis of the von Willebrand factor gene in type 1 von Willebrand disease using conformation sensitive gel electrophoresis: a comparison of fluorescent and manual techniques. Haematologica. 2007 Apr;92(4):550-3.</citation>
    <PMID>17488667</PMID>
  </results_reference>
  <results_reference>
    <citation>Budde U, Schneppenheim R, Eikenboom J, Goodeve A, Will K, Drewke E, Castaman G, Rodeghiero F, Federici AB, Batlle J, Pérez A, Meyer D, Mazurier C, Goudemand J, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost. 2008 May;6(5):762-71. doi: 10.1111/j.1538-7836.2008.02945.x. Epub 2008 Mar 1.</citation>
    <PMID>18315556</PMID>
  </results_reference>
  <results_reference>
    <citation>Haberichter SL, Castaman G, Budde U, Peake I, Goodeve A, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill FG, Montgomery RR. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood. 2008 May 15;111(10):4979-85. doi: 10.1182/blood-2007-09-110940. Epub 2008 Mar 14.</citation>
    <PMID>18344424</PMID>
  </results_reference>
  <results_reference>
    <citation>Costa-Pinto J, Pérez-Rodríguez A, del C Goméz-del-Castillo M, Lourés E, Rodríguez-Trillo A, Batlle J, López-Fernández MF. Diagnosis of inherited von Willebrand disease: comparison of two methodologies and analysis of the discrepancies. Haemophilia. 2014 Jul;20(4):559-67.</citation>
    <PMID>25077350</PMID>
  </results_reference>
  <results_reference>
    <citation>Batlle J, López-Fernández MF, Fraga EL, Trillo AR, Pérez-Rodríguez MA. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease. Blood Coagul Fibrinolysis. 2009 Mar;20(2):89-100. doi: 10.1097/MBC.0b013e3283254570. Review.</citation>
    <PMID>19786936</PMID>
  </results_reference>
  <results_reference>
    <citation>Eikenboom J, Hilbert L, Ribba AS, Hommais A, Habart D, Messenger S, Al-Buhairan A, Guilliatt A, Lester W, Mazurier C, Meyer D, Fressinaud E, Budde U, Will K, Schneppenheim R, Obser T, Marggraf O, Eckert E, Castaman G, Rodeghiero F, Federici AB, Batlle J, Goudemand J, Ingerslev J, Lethagen S, Hill F, Peake I, Goodeve A. Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study. J Thromb Haemost. 2009 Aug;7(8):1304-12. doi: 10.1111/j.1538-7836.2009.03486.x. Epub 2009 Jun 30.</citation>
    <PMID>19566550</PMID>
  </results_reference>
  <results_reference>
    <citation>Eikenboom J, Van Marion V, Putter H, Goodeve A, Rodeghiero F, Castaman G, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost. 2006 Apr;4(4):774-82.</citation>
    <PMID>16634746</PMID>
  </results_reference>
  <results_reference>
    <citation>Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, Meyer D, Fressinaud E, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006 Apr;4(4):766-73.</citation>
    <PMID>16634745</PMID>
  </results_reference>
  <results_reference>
    <citation>Rodeghiero F, Castaman G, Tosetto A, Batlle J, Baudo F, Cappelletti A, Casana P, De Bosch N, Eikenboom JC, Federici AB, Lethagen S, Linari S, Srivastava A. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost. 2005 Dec;3(12):2619-26. Erratum in: J Thromb Haemost. 2006 Apr;4(4):925.</citation>
    <PMID>16359502</PMID>
  </results_reference>
  <results_reference>
    <citation>Penas N, Pérez-Rodríguez A, Torea JH, Lourés E, Noya MS, López-Fernández MF, Batlle J. von Willebrand disease R1374C: type 2A or 2M? A challenge to the revised classification. High frequency in the northwest of Spain (Galicia). Am J Hematol. 2005 Nov;80(3):188-96.</citation>
    <PMID>16247740</PMID>
  </results_reference>
  <results_reference>
    <citation>Corrales I, Ramírez L, Altisent C, Parra R, Vidal F. The study of the effect of splicing mutations in von Willebrand factor using RNA isolated from patients' platelets and leukocytes. J Thromb Haemost. 2011 Apr;9(4):679-88. doi: 10.1111/j.1538-7836.2011.04204.x.</citation>
    <PMID>21251206</PMID>
  </results_reference>
  <results_reference>
    <citation>Corrales I, Ramírez L, Ayats J, Altisent C, Parra R, Vidal F. Integration of molecular and clinical data of 40 unrelated von Willebrand Disease families in a Spanish locus-specific mutation database: first release including 58 mutations. Haematologica. 2010 Nov;95(11):1982-4. doi: 10.3324/haematol.2010.028977. Epub 2010 Aug 26.</citation>
    <PMID>20801902</PMID>
  </results_reference>
  <results_reference>
    <citation>Corrales I, Ramírez L, Altisent C, Parra R, Vidal F. Rapid molecular diagnosis of von Willebrand disease by direct sequencing. Detection of 12 novel putative mutations in VWF gene. Thromb Haemost. 2009 Mar;101(3):570-6.</citation>
    <PMID>19277422</PMID>
  </results_reference>
  <results_reference>
    <citation>Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, Meyer D, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Lethagen S, Hill FG, Peake I. A comparison between two semi-quantitative bleeding scales for the diagnosis and assessment of bleeding severity in type 1 von Willebrand disease. Haemophilia. 2011 Jan;17(1):165-6. doi: 10.1111/j.1365-2516.2010.02381.x.</citation>
    <PMID>21199188</PMID>
  </results_reference>
  <results_reference>
    <citation>Castaman G, Goodeve A, Eikenboom J; European Group on von Willebrand Disease. Principles of care for the diagnosis and treatment of von Willebrand disease. Haematologica. 2013 May;98(5):667-74. doi: 10.3324/haematol.2012.077263. Review.</citation>
    <PMID>23633542</PMID>
  </results_reference>
  <results_reference>
    <citation>Eikenboom J, Federici AB, Dirven RJ, Castaman G, Rodeghiero F, Budde U, Schneppenheim R, Batlle J, Canciani MT, Goudemand J, Peake I, Goodeve A; MCMDM-1VWD Study Group. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. Blood. 2013 Mar 21;121(12):2336-9. doi: 10.1182/blood-2012-09-455089. Epub 2013 Jan 24.</citation>
    <PMID>23349392</PMID>
  </results_reference>
  <results_reference>
    <citation>Mancuso DJ, Tuley EA, Westfield LA, Worrall NK, Shelton-Inloes BB, Sorace JM, Alevy YG, Sadler JE. Structure of the gene for human von Willebrand factor. J Biol Chem. 1989 Nov 25;264(33):19514-27.</citation>
    <PMID>2584182</PMID>
  </results_reference>
  <results_reference>
    <citation>Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, Federici AB; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006 Oct;4(10):2103-14. Epub 2006 Aug 2. Review.</citation>
    <PMID>16889557</PMID>
  </results_reference>
  <results_reference>
    <citation>Bellissimo DB, Christopherson PA, Flood VH, Gill JC, Friedman KD, Haberichter SL, Shapiro AD, Abshire TC, Leissinger C, Hoots WK, Lusher JM, Ragni MV, Montgomery RR. VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population. Blood. 2012 Mar 1;119(9):2135-40. doi: 10.1182/blood-2011-10-384610. Epub 2011 Dec 23.</citation>
    <PMID>22197721</PMID>
  </results_reference>
  <results_reference>
    <citation>Flood VH, Gill JC, Christopherson PA, Bellissimo DB, Friedman KD, Haberichter SL, Lentz SR, Montgomery RR. Critical von Willebrand factor A1 domain residues influence type VI collagen binding. J Thromb Haemost. 2012 Jul;10(7):1417-24. doi: 10.1111/j.1538-7836.2012.04746.x.</citation>
    <PMID>22507569</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Spanish Society of Thrombosis and Haemostasis</investigator_affiliation>
    <investigator_full_name>Francisco Javier Batlle Fonrodona</investigator_full_name>
    <investigator_title>Senior Researcher INIBIC. A Coruña. SPAIN</investigator_title>
  </responsible_party>
  <keyword>von Willebrand disease (VWD)</keyword>
  <keyword>von Willebrand factor (VWF)</keyword>
  <keyword>von Willebrand factor gene</keyword>
  <keyword>next generation sequencing</keyword>
  <keyword>diagnosis</keyword>
  <keyword>VWD Spanish Cohort</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Von Willebrand Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

